EUCTR2017-001465-24-BE进行中（未招募）1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. All adult and pediatric subjects who received at least one GM T cell infusion in a previous Celgene-sponsored or Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
- •2. Subject (and, parental/legal representative, when applicable) must understand and voluntarily sign an Informed Consent Form (ICF) / Informed Assent Form (IAF) prior to any study-related assessments/procedures being conducted.
- •3. Not applicable as of Protocol Amendment 01: Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 91
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 238
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 196
排除标准
- •Not Applicable.
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.EUCTR2017-001465-24-NLCelgene Corporation218
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-NOCelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-DECelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with JCAR015B-cell Acute Lymphoblastic Leukemia (ALL)MedDRA version: 19.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2016-003400-31-BECelgene Corporation105
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-GBCelgene Corporation525